Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Climb Bio Inc (CLYM)

Climb Bio Inc (CLYM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Tue Nov 25, 6:00AM CST

WELLESLEY HILLS, Mass., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today...

CLYM : 1.7300 (-0.57%)
Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire - Thu Nov 6, 6:01AM CST

PrisMN Phase 2 trial of budoprutug in Primary Membranous Nephropathy (pMN) initiated  Phase 1 trial of budoprutug subcutaneous formulation initiated, with initial data expected in H1 2026 Clinical...

CLYM : 1.7300 (-0.57%)
Climb Bio to Present at Upcoming Investor Conferences GlobeNewswire - Mon Nov 3, 6:00AM CST

WELLESLEY HILLS, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 1.7300 (-0.57%)
Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy GlobeNewswire - Tue Oct 21, 6:00AM CDT

WELLESLEY HILLS, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 1.7300 (-0.57%)
Analysts’ Top Healthcare Picks: Climb Bio (CLYM), Wave Life Sciences (WVE) Tipranks - Fri Oct 17, 6:26AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Climb Bio (CLYM – Research Report) and Wave Life Sciences (WVE – Research Report) with bullish sentiments.Elevate...

CLYM : 1.7300 (-0.57%)
WVE : 7.62 (+6.72%)
Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 GlobeNewswire - Fri Oct 17, 6:00AM CDT

Preclinical data for CLYM116, anti-APRIL monoclonal antibody, highlight favorable pharmacokinetic and pharmacodynamic profile, supporting development for IgA nephropathy (IgAN) Long-term follow-up...

CLYM : 1.7300 (-0.57%)
Climb Bio Appoints New CFO Susan Altschuller Tipranks - Thu Oct 2, 5:02PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Climb Bio...

CLYM : 1.7300 (-0.57%)
Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer GlobeNewswire - Wed Oct 1, 6:00AM CDT

WELLESLEY HILLS, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 1.7300 (-0.57%)
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN GlobeNewswire - Mon Sep 29, 6:00AM CDT

New preclinical data demonstrate deeper IgA reduction and a longer half-life compared to first-generation anti-APRIL monoclonal antibody CLYM116 Phase 1 trial initiation expected in Q4 2025, with...

CLYM : 1.7300 (-0.57%)
Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025 GlobeNewswire - Thu Sep 4, 6:00AM CDT

WELLESLEY HILLS, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced...

CLYM : 1.7300 (-0.57%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot